Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprost and Dorzolamide in Pediatric Glaucoma
NCT01527682Phase 2Completed
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jul 2009
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of latanoprost ophthalmic solution 0.005% (TearClear TC-002) and dorzolamide in primary congenital glaucoma (PCG), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Percentage of Eyes With Response at 3 years. Started Jul 2009; status: completed.
02
Drugs
latanoprost ophthalmic solution 0.005% (TearClear TC-002)dorzolamide
03
Conditions
primary congenital glaucoma (PCG)
Beyond the preview
Go deeper on NCT01527682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01527682.